Figure 4: Cell-autonomous effect of malignant progression in Asxl2+/− and Asxl2−/− mice. | Nature Communications

Figure 4: Cell-autonomous effect of malignant progression in Asxl2+/− and Asxl2−/− mice.

From: Loss of Asxl2 leads to myeloid malignancies in mice

Figure 4

(a) The kinetics of CD45.2 chimerism in the PB of mice receiving WT, Asxl2+/− or Asxl2−/− BM cells (mean±s.e.m., four to eight mice per genotype). (b) The kinetics of percent Mac1+ cells in CD45.2+ cells of mice receiving WT, Asxl2+/− or Asxl2−/− BM cells (mean±s.e.m., four to eight mice per genotype). (c) Kaplan–Meier curve shows the per cent survival of mice received WT, Asxl2+/− or Asxl2−/− BM cells over time. (d) Flow cytometric analysis of cKit+ cells in BM. (e) Representative gross appearance of spleens and bones. (f) Representative images of May–Grünwald–Giemsa-stained cytospin preparations of BM and spleen cells from representative leukemic mice receiving Asxl2−/− BM cells. Red arrows indicate myeloblastic cells. Scale bar, 10 μm. (g) H&E-stained sections of the femurs, spleens and livers, and MPO-stained spleen sections from a representative leukemic recipient mouse transplanted with Asxl2−/− BM cells and a recipient mouse receiving WT BM cells. Scale bar, 100 μm.

Back to article page